Skip to main content Accessibility help
×
Home

Deregulated Expression of the Per1 and Per2 in Human Gliomas

  • He-chun Xia (a1), Zhan-feng Niu (a1), Hui Ma (a1), Shuan-zhu Cao (a1), Shao-cai Hao (a1), Zhong-tao Liu (a1) and Fan Wang (a1)...

Abstract

Background:

Growing evidence shows that the deregulation of the circadian clock plays an important role in the development of malignant tumors, including gliomas. However, the molecular mechanisms of genes controlling circadian rhythm in glioma cells have not been explored.

Methods:

Using reverse transcription polymerase chain reaction and immunohistochemistry techniques, we examined the expression of two important clock genes, Per1 and Per2, in 33 gliomas.

Results:

In this study, out of 33 gliomas, 28 were Per1-positive, and 23 were Per2-positive. The expression levels of Per1 and Per2 in glioma cells were significantly different from the surrounding non-glioma cells (P<0.01). The difference in the expression rate of Per1 and Per2 in high-grade (grade III and IV) and low-grade (grade 1 and II) gliomas was insignificant (P>0.05). While there was no difference in the intensity of immunoactivity for Per2 between high-grade gliomas and low-grade gliomas (r=-0.330, P=0.061), the expression level of Per1 in highgrade gliomas was significantly lower than that in low-grade gliomas(r=-0.433, P=0.012).

Conclusions:

In this study, we found that the expression of Per1 and Per2 in glioma cells was much lower than in the surrounding non-glioma cells. Therefore, we suggest that disturbances in Per1 and Per2 expression may result in the disruption of the control of normal circadian rhythm, thus benefiting the survival of glioma cells. Differential expression of circadian clock genes in glioma and non-glioma cells may provide a molecular basis for the chemotherapy of gliomas.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Deregulated Expression of the Per1 and Per2 in Human Gliomas
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Deregulated Expression of the Per1 and Per2 in Human Gliomas
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Deregulated Expression of the Per1 and Per2 in Human Gliomas
      Available formats
      ×

Copyright

Corresponding author

Department of Neurosurgery in the Affiliated Hospital of Ningxia Medical University, Yinchuan, 75004, China.

References

Hide All
1. Gromeier, M, Wimmer, E. Viruses for the treatment of malignant glioma. Curr Opin Mol Ther. 2001; 3 (5): 5038.
2. Rainov, N, Ren, H. Gene therapy for human malignant brain tumors. Cancer J. 2003; 9 (3): 1808.
3. Aschhoff, B. Retrospective study of Ukraine treatment in 203 patients with advanced-stage tumors. Drugs Exp Clin Res. 2000; 26 (5-6): 24952.
4. Sun, JY, Yang, H, Miao, S, Li, JP, Wang, SW, Zhu, MZ, et al. Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. J Phymed. 2009; 16 (11): 10704.
5. Stummer, W. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7 (5): 392401.
6. Fujioka, A, Takashima, N, Shigeyoshi, Y. Circadian rhythm generation in a glioma cell line. Biochem Biophys Res Commun. 2006; 346 (1): 16974.
7. Perou, CM, Serlie, T, Eisen, MB, van de Rijn, M, Jeffrey, SS, Rees, CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 74752.
8. Lerebours, F, Lidereau, R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 2002; 44 (2): 12141.
9. Widschwendter, M, Jones, PA. DNA methylation and breast carcinogenesis. Oncogene. 2002; 21 (35): 546282.
10. Balsalobre, A. Clock genes in mammalian peripheral tissues. Cell Tissue Res. 2002; 309 (1): 1939.
11. Reppert, SM, Weaver, DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 2001; 63: 64776.
12. Metz, RP, Qu, X, Laffin, B, Earnest, D, Perter, WW. Circadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn. 2006; 235 (1): 26371.
13. Chen, ST, Choo, KB, Hou, MF, Yeh, KT, Kuo, SJ, Chang, JG. Deregulated expression of the Per1, Per2, Per3 genes in breast cancers. Carcinogenesis. 2005; 26 (7): 12416.
14. Filipski, E, King, VM, Li, X, Granda, TG, Mormont, MC, Liu, X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94 (9): 6907.
15. Yeh, KT, Yang, MY, Liu, TC, Chen, JC, Chan, WL, Lin, SF, et al. Abnormal expression of Period 1 (Per1) in endometrial carcinoma. J Pathol. 2005; 206 (1): 11120.
16. Hua, H, Wang, Y, Wan, C, Liu, Y, Zhu, B, Wang, X, et al. Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther. 2007; 14 (9): 81518.
17. Tcrpe, HJ, Storkel, S, Zimmer, U, Anquez, V, Fischer, C, Pantel, K, et al. Expression of CD44 isoforms in renal cell tumors. Am J Pathol. 1996; 148 (2): 45363.
18. Bjarnason, GA, Jordan, R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog Cell Cycle Res. 2000; 4: 193206.
19. Matsuo, T, Yamaguchi, S, Mitsui, S, Emi, A, Shimoda, F, Okamura, H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003; 302 (5643): 2559.
20. Smaaland, R, Lote, K, Sothern, RB, Laerum, OD. DNA synthesis and ploidy in non-Hodgkin’s lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res. 1993; 53: 312938.
21. Panda, S, Antoch, MP, Miller, BH, Su, AI, Schock, AB, Straume, M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002; 109 (3): 30720.
22. Storch, KF, Lipan, O, Leykin, I, Viswanathan, N, Davis, FC, Wong, WH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417 (6884): 7883.
23. Duffield, GE, Best, JD, Meurers, BH, Bittner, A, Loros, JJ, Dunlap, JC. Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells. Curr Biol. 2002; 12 (7): 5517.
24. Kornmann, B, Preitner, N, Rifat, D, Fleuury-Olela, F, Schibler, U. Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of differentially expressed mRNAs. Nucl Acids Res. 2001; 29 (11): E51.
25. Le Minh, N, Damiola, F, Tronche, F, Schutz, G, Schibler, U. Glucocorticoid hormones inhibit food-induced phaseshifting of peripheral circadian oscillators. EMBO J. 2001; 20 (24): 712836.
26. Hrushesky, WJM, Bjarnason, GA. Circadian cancer therapy. J Clin Oncol. 1993; 11 (7): 140317.
27. Levi, F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001; 2 (5): 30715.
28. Focan, C. Circadian rhythms and cancer chronotherapy. Pharmacol Ther. 1995; 67 (1): 152.
29. Mormont, MC, Levi, F. Cancer chronotherapy: principle, applications and perspectives. Cancer. 2003; 97 (1): 15569.
30. Fu, L, Pelicano, H, Liu, J, Huang, P, Lee, C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111 (1): 4150.
31. Lee, CC. Tumor suppression by the mammalian Period genes. Cancer Causes Control. 2006; 17 (4): 52530.

Deregulated Expression of the Per1 and Per2 in Human Gliomas

  • He-chun Xia (a1), Zhan-feng Niu (a1), Hui Ma (a1), Shuan-zhu Cao (a1), Shao-cai Hao (a1), Zhong-tao Liu (a1) and Fan Wang (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed